According to the research report titled ‘U.S. Influenza (Flu) Vaccines Market - Growth, Demand, Trends, Opportunity, Forecasts (2021 - 2028)’, available with MarketStudyReport, U.S. influenza (flu) vaccines market is estimated to be worth USD 5.5 billion by the end of the forecast period 2021-2028.
 

As per the report findings, increasing awareness about diseases, rising research & development activities, and growing efforts by governments and authorities to promote vaccinations are driving the U.S. influenza (flu) vaccines market growth.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3890160/
 

For those unversed, influenza (flu) vaccines instigate the development of antibodies in the body approximately two weeks after administration. These antibodies act against infection from viruses that are used to make vaccine. Thus, flu vaccines effectively protect against influenza viruses that are expected to be rampant during the upcoming season.
 

Notably, the introduction of quadrivalent influenza vaccines, and the advent of the coronavirus pandemic are also expected to spur market demand in the upcoming years.
 

Apart from elaborating on key growth drivers, the research report evaluates the number of people (adults, and children) being vaccinated for influenza in the U.S., along with forecasts for the next seven years.
 

Furthermore, it comprehensively analyzes the U.S. influenza (flu) vaccines market with respect to rapid diagnostic testing management, distribution channels, techniques of vaccination, regulatory framework as well as reimbursement patterns prevailing in the region.
 

Moving on to the competitive scope, Versatope Therapeutics Inc., EpiVax Inc., Imutex Ltd., FluGen Inc., Daiichi Sankyo Co. Ltd., Pneumagen Ltd., Moderna Inc., Medicago Inc., BiondVax Pharmaceuticals Ltd., Novavax Inc., AstraZeneca plc, Seqirus UK Ltd., GlaxoSmithKline plc, and Sanofi Pasteur are the prominent players influencing U.S. influenza (flu) vaccines industry. The report dissects production & supply volumes, as well as demand & allocation of each of the listed companies to provide a holistic view of the market dynamics.
 

It further highlights the major strategic developments in the industry including mergers & acquisitions, licensing agreements, collaboration deals, distribution agreements, exclusive agreements, and promising influenza vaccines in clinical development.